These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 1623255)
21. Parkinson's disease in 1984: an update. Lang AE; Blair RD Can Med Assoc J; 1984 Nov; 131(9):1031-7. PubMed ID: 6388779 [TBL] [Abstract][Full Text] [Related]
22. MPTP and the aetiology of Parkinson's disease. Clinical implications. London, June 27, 1985. J Neural Transm Suppl; 1986; 20():1-81. PubMed ID: 3489069 [No Abstract] [Full Text] [Related]
23. Biochemical aspects of Parkinson's disease. Nagatsu T Adv Neurol; 1993; 60():165-74. PubMed ID: 8093575 [No Abstract] [Full Text] [Related]
25. Environmental neurotoxic chemicals-induced ubiquitin proteasome system dysfunction in the pathogenesis and progression of Parkinson's disease. Sun F; Kanthasamy A; Anantharam V; Kanthasamy AG Pharmacol Ther; 2007 Jun; 114(3):327-44. PubMed ID: 17521740 [TBL] [Abstract][Full Text] [Related]
26. "Ottorino Rossi" Award 2000. New targets for therapy in Parkinson's disease: pathogenesis and pathophysiology. Greenamyre JT Funct Neurol; 2000; 15(2):67-80. PubMed ID: 10916718 [No Abstract] [Full Text] [Related]
27. [Contribution of MPTP to studies on the pathogenesis of Parkinson's disease]. Mizuno Y Rinsho Shinkeigaku; 1989 Dec; 29(12):1494-6. PubMed ID: 2698296 [TBL] [Abstract][Full Text] [Related]
28. The role of iron in senescence of dopaminergic neurons in Parkinson's disease. Youdim MB; Riederer P J Neural Transm Suppl; 1993; 40():57-67. PubMed ID: 8294901 [TBL] [Abstract][Full Text] [Related]
30. [Neurobiologic and pharmacologic studies on the pathogenesis of Parkinson disease]. Brücke T; Riederer P Wien Med Wochenschr; 1986 Aug; 136(15-16):401-8. PubMed ID: 2878540 [TBL] [Abstract][Full Text] [Related]
31. Parkinson's disease: return of an old prime suspect. Sulzer D; Schmitz Y Neuron; 2007 Jul; 55(1):8-10. PubMed ID: 17610813 [TBL] [Abstract][Full Text] [Related]
32. The role of iron in Parkinson disease and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. Yantiri F; Andersen JK IUBMB Life; 1999 Aug; 48(2):139-41. PubMed ID: 10794588 [TBL] [Abstract][Full Text] [Related]
33. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease. Löschmann PA; Wüllner U; Heneka MT; Schulz JB; Kunow M; Wachtel H; Klockgether T Synapse; 1997 Aug; 26(4):381-91. PubMed ID: 9215597 [TBL] [Abstract][Full Text] [Related]
35. Development of new pharmacological approaches in Parkinson's disease. Carlsson A Adv Neurol; 1987; 45():513-8. PubMed ID: 3493631 [No Abstract] [Full Text] [Related]
37. Type B monoamine oxidase and neurotoxins. Naoi M; Maruyama W Eur Neurol; 1993; 33 Suppl 1():31-7. PubMed ID: 8375430 [TBL] [Abstract][Full Text] [Related]
38. Trichloroethylene: Parkinsonism and complex 1 mitochondrial neurotoxicity. Gash DM; Rutland K; Hudson NL; Sullivan PG; Bing G; Cass WA; Pandya JD; Liu M; Choi DY; Hunter RL; Gerhardt GA; Smith CD; Slevin JT; Prince TS Ann Neurol; 2008 Feb; 63(2):184-92. PubMed ID: 18157908 [TBL] [Abstract][Full Text] [Related]
39. Antiparkinsonian effects of remacemide hydrochloride, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Greenamyre JT; Eller RV; Zhang Z; Ovadia A; Kurlan R; Gash DM Ann Neurol; 1994 Jun; 35(6):655-61. PubMed ID: 8210221 [TBL] [Abstract][Full Text] [Related]
40. Future strategies for the treatment of Parkinson's disease. Fahn S Adv Neurol; 1993; 60():636-40. PubMed ID: 8420202 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]